UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
One company is providing investors with the opportunity to contribute to novel mental health care solutions by participating in the growth of companies in the psychedelics...
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Return Health is exploring psychedelic derivatives for the treatment of dementia.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
MindMed is expected to begin enrolling patients immediately into its proof-of-concept exploratory trial for the use of LSD to treat adult ADHD.
The acquisition includes all future worldwide rights relating to the use of psychedelics to treat Alzheimer’s disease and other dementias.
The new guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) stating that the use of real-world data from clinical trials could help with...
A new report from the Conservative Drug Policy Reform Group (CDPRG) has shown the majority of MPs in the UK support drug policy reform, and highlights...
With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...
Braxia Scientific has dosed the first patients in its multi-dose psilocybin clinical trial exploring the compound’s efficacy for treatment-resistant depression (TRD).
Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer...
